Jade Biosciences develops monoclonal antibody therapies for autoimmune diseases, with company updates centered on clinical execution, pipeline expansion, and financing. Its lead program, JADE101, targets APRIL and is being developed for immunoglobulin A nephropathy; additional programs include JADE201, a half-life extended afucosylated anti-BAFF receptor antibody, and JADE301, an antibody program in preclinical development.
Recurring news includes financial results, corporate updates, clinical and biomarker data presentations, research conference participation, private placement financing, equity inducement grants, and leadership changes tied to the company's research and development organization.
Jade Biosciences (Nasdaq: JBIO) will host a conference call and webcast on June 1, 2026, at 8:00 a.m. ET to discuss interim Phase 1 healthy volunteer results for JADE101, an anti-APRIL monoclonal antibody in development for IgA nephropathy.
Jade Biosciences (Nasdaq: JBIO) has dosed the first participant in a first-in-human Phase 1 trial of JADE201, an investigational half-life extended afucosylated anti-BAFF receptor monoclonal antibody for rheumatoid arthritis.
The randomized, placebo-controlled single ascending dose study will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and biomarkers, with interim data expected in 2027. Preclinical data showed dose-dependent BAFF-R occupancy, extended half-life, and sustained B cell depletion in non-human primates, supporting potential for infrequent subcutaneous dosing across autoimmune diseases.
Jade Biosciences (Nasdaq: JBIO) dosed the first participant in JUNIPER, its open-label Phase 2 trial of JADE101 for IgA nephropathy (IgAN). The study will enroll about 30 participants and assess safety, urine protein-to-creatinine ratio, renal function, and hematuria.
Interim Phase 2 data are expected in 2027.
Jade Biosciences (Nasdaq: JBIO) reported first quarter 2026 results and provided a corporate update on May 7, 2026. The company held $311.3 million in cash, cash equivalents, and investments as of March 31, 2026, which it expects will fund operations into the first half of 2028.
Key clinical milestones: biomarker-rich Phase 1 JADE101 data to be presented at the 63rd ERA Congress; Phase 2 JADE101 in IgA nephropathy to start in Q2 2026 with interim 2027 data; Phase 1 JADE201 to start in Q2 2026; JADE301 first-in-human expected H1 2027. Management added a new CMO and promoted its R&D president.
Jade Biosciences (Nasdaq: JBIO) announced an inducement equity award tied to the appointment of Edward R. Conner, M.D., as Chief Medical Officer, effective April 22, 2026. The Board granted non-qualified stock options to purchase 500,000 shares under the Inducement Plan.
The options have an exercise price of $25.38 (equal to the April 22, 2026 closing price), vest over four years (25% at one year, then monthly vesting), and the company intends to file a Form S-8 to register the issuable shares.
Jade Biosciences (Nasdaq: JBIO) appointed Edward R. Conner, M.D., as Chief Medical Officer effective April 22, 2026.
Dr. Conner will lead clinical and medical strategy to advance JADE101, initiate a Phase 2 trial in IgA nephropathy, and move JADE201 and JADE301 into the clinic; Andrew King is expanded to President of R&D.
Dr. Conner joins from Ardelyx and previously held senior clinical roles at Third Harmonic Bio, Locanabio, Audentes/Astellas, Sangamo and Genentech; he earned an M.D. from UCSF.
Jade Biosciences (Nasdaq: JBIO) reported Q4 and full‑year 2025 results and provided a corporate update on its autoimmune pipeline and financing.
Key items: $336.2 million cash and investments as of December 31, 2025, expected runway into the first half of 2028; JADE101 Phase 1 interim data expected Q2 2026; JADE101 Phase 2 in IgA nephropathy to start mid‑2026 with preliminary 2027 data; JADE201 first‑in‑human trial to begin Q2 2026; JADE301 nominated with Phase 1 planned H1 2027; completed private financings raising ~$180 million.
Jade Biosciences (Nasdaq: JBIO) will participate in multiple investor conferences in late February and March 2026, including Oppenheimer, TD Cowen, Leerink, and Jefferies.
Management will present, host fireside chats, and hold one-on-one investor meetings. According to the company, live webcasts will be available on the Events & Presentations page with replays archived for 90 days.
Jade Biosciences (Nasdaq: JBIO) outlined 2026 objectives to advance a pipeline of monoclonal antibodies across autoimmune diseases and will present at the J.P. Morgan Healthcare Conference on January 15, 2026.
Key program milestones include JADE101 Phase 1 interim biomarker data in H1 2026 and a planned Phase 2 start in mid-2026 for IgA nephropathy; JADE201 first-in-human start in Q2 2026 with interim data expected in 2027; and nominated JADE301 entering first-in-human study in H1 2027. The company reported approximately $336 million cash and investments as of December 31, 2025, expected to fund operations into H1 2028.
Jade Biosciences (Nasdaq: JBIO) entered a securities purchase agreement with BB Biotech for a $45 million private placement, selling 3,214,286 shares of common stock at $14.00 per share. The private placement is expected to close on or about December 16, 2025, subject to customary closing conditions.
The company said it intends to use net proceeds to fund research and development, general corporate expenses, and working capital. The sale is a private transaction and the shares are unregistered; Jade agreed to file a registration statement with the SEC to register resale of the shares under a registration rights agreement.